Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

Researchers have demonstrated the efficacy of a compact, specific and AAV-compatible CRISPR-Cas13 variant, Cas13bt3, for RNA-targeted gene therapy...

Researchers in the US report a potentially new therapeutic strategy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Using...

A new CRISPR-dCas13 tool developed by French researchers modulates alternative splicing without altering gene expression. The RNA-editing system,...

In an article just published in Science, researchers at University of California Berkeley, Gladstone Institutes (San Francisco) and Lawrence Berkeley...

Based on an evolved bacterial adenosine deaminase, DECOR represents a significant advancement in RNA editing technology by providing a more precise,...